SINGLE-CENTRE/OPEN LABEL, 24 WEEKS, PHASE I CLINICAL TRIAL OF ANCILLA DOMINI D-2 INVERSE TRANSCRIPTION THERAPEUTICS ON DIABETES (II)

Single-Centre/Open Label, 24 Weeks, Phase I Clinical Trial Of Ancilla Domini Chota-D-2 Inverse Transcription Therapeutics On Diabetes (II)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202409885980073

Enrollment

Registered

2024-09-16

Start date

2024-11-11

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

Ancilla Domini CHoTTA D2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults 18+ years old 2. Male/Female 3. Residing in any part of Ghana 4. Open to all nationaities/race 5. People diagnosed of Diabetes Mellitus Type (II)/NON-INSULIN DEPENDENT DIABETES

Exclusion criteria

Exclusion criteria: 1. Children/under 18 years old 2. Pregnant/ Lactating Mothers 3. Diabetes Mellitus (I)/ Insulin dependent Diabetes.

Design outcomes

Primary

Measure	Time frame
Over 80% Research candidates' Diabetes (II) shall be cured;All the research participants shall experience little/no intervention-associated side effects	—

Secondary

Measure	Time frame
Complications of Diabetes shall be halted/prevented/reversed in over 80% of research enrollees ;Over 80% of research subjects' blood glucose shall normalize permanently	—

Countries

Ghana

Contacts

Public ContactAlee Geoffrey

Public Relations Executive of Ancilla Domini International Researchers

denudation2015@gmail.com+2347041388422

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026